Indaiatuba

Attention Deficit Hyperactivity Disorder (ADHD) affects 3-5% of school-age children worldwide, causing symptoms like inattention, hyperactivity, and impulsivity. Researchers are evaluating whether a virtual reality (VR) exergame called "Move Sapiens" combined with a short High-Intensity Interval Training (HIIT) model can improve attention and executive function in adolescents aged 12 to 17 with ADHD. The study also aims to see if this intervention can reduce related symptoms such as sleep problems and anxiety. Participants will be randomly assigned to two groups: one practicing the "Move Sapiens" exergame with HIIT exercise cycles, and the other using a control version of the exergame without physical exercise, controlled via joystick. The intervention lasts 4 weeks, with 20 sessions total—5 supervised in the lab and 15 done at home with remote monitoring. Each HIIT session includes 12 cycles of 16 seconds of maximum effort followed by 20 seconds of rest, totaling about 7 minutes. Heart rate and game scores are monitored during lab sessions. During the study, participants will visit the clinic for assessments before and after the intervention. Researchers will collect data using questionnaires, cognitive tests, and monitoring of attention and inhibitory control scores. A smaller group will undergo brain imaging to explore potential brain changes. The study measures safety, effectiveness, and clinical relevance of the VR HIIT exergame intervention over the 4-week period.

Researchers are evaluating the effect of tozorakimab, added to standard care, in adults hospitalized with viral lung infection who need supplemental oxygen. The study focuses on preventing death or progression to invasive mechanical ventilation or extracorporeal membrane oxygenation by day 28. This is a Phase III, multicenter, randomized, double-blind trial comparing tozorakimab to placebo in patients with viral lung infection causing acute respiratory failure. Participants will receive a single intravenous dose of either tozorakimab or a matching placebo on the first day of the study. Both groups continue to receive standard care for their viral lung infection. The study is designed to assess the safety and efficacy of tozorakimab as an add-on therapy in this patient population. Throughout the study, researchers will monitor participants for survival and the need for invasive mechanical ventilation or ECMO up to 28 days after treatment. The main outcome measured is the proportion of patients who die or require mechanical ventilation or ECMO by day 28. Participants will be closely observed during hospitalization, with data collected on their respiratory status and treatment outcomes to evaluate the study drug's impact and safety.